Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5438 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AZD5438 | DRUG | - |
Inclusion Criteria: * Advanced solid malignancy * Cancer refractory to standard treatments or for which no standard therapy exits Exclusion Criteria: * Radiotherapy within 3 weeks of the start of treatment * Investigational product within the last 3 weeks * Systemic cytotoxic anti-cancer therapy ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
AZD5438 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed as a potential oncology therapy, with clinical research focused on patients with advanced solid malignancies.
AZD5438 is being developed by AstraZeneca PLC, a multinational pharmaceutical company. AstraZeneca's stock is traded under the ticker symbol AZN on major stock exchanges. The company is conducting clinical research on this investigational oncology drug candidate.
AZD5438 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and potential efficacy in patients with advanced solid malignancies.
AZD5438 has been studied in one clinical trial, identified as NCT00088790, titled "AZD5438 in Patients With Advanced Solid Malignancies." This Phase 1 trial was conducted in the United States and enrolled adult patients aged 18 years and older with neoplasms. The trial has been completed.
AZD5438 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The drug remains in clinical development and has not received regulatory approval for any indication.